The transplacental transfer of NHC, the active metabolite of molnupiravir, in the ex vivo human placental perfusion model
Canadian Journal of Physiology and Pharmacology · 01.01.2026 · 104 · 1-9
DOI: 10.1139/cjpp-2025-0363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.01.2026. Verfasst von Magdalene Zabek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Placenta, Maternal-Fetal Exchange, Cytidine, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Health Research Institute, London Health Sciences Research Institute, Western University.
Abstract (Originalsprache)
Pregnant patients with COVID-19 have an increased risk for negative birthing outcomes such as preterm birth and low birth weight. Molnupiravir, an antiviral used to treat COVID-19, has limited data in pregnancy. Animal studies suggest embryotoxic and mutagenic potential, therefore placental transfer must be characterized to assess fetal risk. This medication may be necessary if the pregnant patient is critically ill. The objective of this study is to determine the rate and extent of placental transfer of molnupiravir. The transplacental pharmacokinetics of the active metabolite of molnupiravir, β-d- N 4 -hydroxycytidine (NHC), were determined using the ex vivo human placental perfusion model. NHC was introduced into the maternal circuit at therapeutic concentrations (2.97 µg/mL) ( n = 4) or 10-times therapeutic concentrations (29.7 µg/mL) ( n = 4) and transfer was observed over 3 h and then quantified by liquid chromatography mass spectrometry. NHC was detectable on the fetal side within 10 min. The average fetal:maternal concentration ratio was 0.48 for placentas perfused with 2.97 µg/mL, and 0.57 for those perfused with 29.7 µg/mL. These results suggest that significant concentrations of molnupiravir will reach the fetus and given the risk for teratogenicity, this therapeutic should be avoided in pregnancy unless maternal morbidity is severe and no safer alternatives exist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
- London Health Sciences Centre Research Institute, London, ON, Canada.
- Children's Health Research Institute, London, ON, Canada.
- Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
- Department of Obstetrics and Gynecology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
ORCID-Profile: Janine R Hutson
Förderung
- Children's Health Research Institute
- London Health Sciences Research Institute
- Western University
- Academic Medical Organization of Southwestern Ontario
Zitieren
APA
Zabek, M., Chan, E., Lim, Y., Urquhart, B., Garcia-Bournissen, F., & Hutson, J. (2026). The transplacental transfer of NHC, the active metabolite of molnupiravir, in the ex vivo human placental perfusion model. Canadian Journal of Physiology and Pharmacology, 104, 1-9. https://doi.org/10.1139/cjpp-2025-0363
Vancouver
Zabek M, Chan E, Lim Y, Urquhart B, Garcia-Bournissen F, Hutson J. The transplacental transfer of NHC, the active metabolite of molnupiravir, in the ex vivo human placental perfusion model. Canadian Journal of Physiology and Pharmacology. 2026;104:1-9. doi:10.1139/cjpp-2025-0363
BibTeX
@article{Zabek2026,
author = {Zabek, Magdalene and Chan, Eddie and Lim, Yong Jin and Urquhart, Bradley L and Garcia-Bournissen, Facundo and Hutson, Janine R},
title = {The transplacental transfer of NHC, the active metabolite of molnupiravir, in the ex vivo human placental perfusion model},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
volume = {104},
pages = {1--9},
doi = {10.1139/cjpp-2025-0363}
}
EUVIMED